BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Servier, Google Cloud Extend Partnership to Accelerate Drug Development with AI

by Illia Petrov   •   Jan. 16, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI & Digital   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Servier, an international pharmaceutical group, and Google Cloud have announced a five-year extension of their collaboration to integrate AI technologies across Servier's R&D, production, and distribution activities. This partnership aims to address challenges in drug development, which currently takes an average of 15 years, by using AI to analyze large datasets, streamline clinical trials, and optimize drug formulations.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Servier plans to leverage Google Cloud’s generative AI tools, including its Gemini large language models, to identify therapeutic targets, profile patient subpopulations, and digitalize clinical trials. Approximately 60 AI use cases have been identified, designed to enhance the probability of success, accelerate time to market, and optimize formulations, particularly for oncology and rare diseases. These AI-driven insights are expected to reduce inefficiencies across the R&D process, providing researchers and clinicians with actionable data in real-time.

See also: 17 Companies Building the Future of Drug Development on a Chip

The partnership also includes deploying AI tools across Servier’s workforce to improve efficiency while adhering to strict data security and confidentiality standards. This marks a continuation of the companies’ collaboration that began in 2022, with the shared goal of leveraging technology to bring innovative therapies to patients more effectively.

Servier’s R&D efforts benefit from over 70 active alliances and collaborations, contributing to its broader innovation ecosystem. The company’s pipeline includes candidates for solid tumors, hematological malignancies, autoimmune conditions, and neurodegenerative diseases like Parkinson’s.

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.